Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

VERNALIS PLC (VER)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 02/20 05:35:11 pm
6.33 GBp   +0.48%
2017VERNALIS : enters into research collaboration with Daiichi Sankyo
AQ
2017VERNALIS : AGM Statement
PU
2017VERNALIS PLC : AGM Statement
MW
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Vernalis plc
Researches and develops pharmaceutical products

Vernalis Plc is a commercial stage pharmaceutical company.

Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market; Moxatag, a once-a-day formulation of the antibiotic and amoxicillin; and frovatriptan, used for the acute treatment of migraine.

Vernalis also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market.

The company was founded by Keith G. McCullagh in 1986 and is headquartered in Winnersh, United Kingdom.

Number of employees : 115 persons.
Sales per Businesses
20162017Delta
GBP (in Million)%GBP (in Million)%
Research & Development8.0466.8%14.4069.3% +79.12%
Commercial3.9933.2%6.3930.7% +59.96%
Sales per Regions
20162017Delta
GBP (in Million)%GBP (in Million)%
Rest of Europe8.1367.6%14.2468.5% +75.05%
Rest of the World2.7322.7%1.989.5% -27.72%
North America1.169.7%4.5822% +293.89%
United Kingdom0.0050%---
Managers
NameAgeSinceTitle
Ian Garland532008Chief Executive Officer & Executive Director
Sandford Sommer-2016President & Chief Operating Officer
Peter John Fellner, PhD742003Non-Executive Chairman
David MacKney502009Chief Financial Officer & Executive Director
Mike Wood-2004Research Director
Pascal Borderies, MD-2014Senior Vice President-Medical Affairs
Carol C. Ferguson712003Senior Independent Non-Executive Director
Nigel Sheail532011Independent Non-Executive Director
Ian David Gilham, PhD582015Independent Non-Executive Director
Lisa Amster Schoenberg, MBA522015Independent Non-Executive Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 526,819,624 520,268,687 98.8% 0 0.0% 98.8%
Shareholders
NameEquities%
Invesco Asset Management Ltd. 194,417,167 36.9%
Woodford Investment Management Ltd. 157,876,138 30.0%
GAM London Ltd. 47,808,756 9.08%
Legal & General Investment Management Ltd. 28,844,930 5.48%
Aviva Investors Global Services Ltd. 23,921,703 4.54%
Medical Strategy GmbH 5,898,929 1.12%
Hargreaves Lansdown Asset Management Ltd. 5,753,000 1.09%
TD Direct Investing (Europe) Ltd. 4,843,000 0.92%
River & Mercantile Asset Management LLP 3,120,000 0.59%
Apo Asset Management GmbH 3,094,000 0.59%
Company contact information
Vernalis Plc
100 Berkshire Place
Wharfedale Road
Winnersh, Berkshire RG41 5RD

Phone : +44.118.938.0000
Fax : +44.118.938.0001
Web : www.vernalis.com
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
VERNALIS PLC-28.98%46
CELLTRION, INC.--.--%36 184
IQVIA HOLDINGS INC6.93%21 157
LONZA GROUP-7.82%18 346
INCYTE CORPORATION-6.91%18 156
NEKTAR THERAPEUTICS40.66%13 138
ALNYLAM PHARMACEUTICALS, INC.-5.56%12 005
ALKERMES PLC8.33%10 343
QIAGEN6.79%7 897
SEATTLE GENETICS, INC.1.05%7 841
SAGE THERAPEUTICS INC-0.67%6 666
IONIS PHARMACEUTICALS INC-3.90%6 246
ICON PLC1.52%6 215
GALAPAGOS17.12%5 866
EXACT SCIENCES CORPORATION-6.59%5 850
UNITED THERAPEUTICS CORPORATION-7.46%5 830
PRA HEALTH SCIENCES INC-2.09%5 634
BIO-TECHNE CORP8.88%5 290
CHARLES RIVER LABORATORIES INTL. INC0.79%5 128
FIBROGEN INC18.99%4 644
ABLYNX111.00%4 069
Connections : Vernalis plc
© 2018 People , Fundamentals and Ownership